The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Phase II EVI-2 study: vitamin C supplementation in patients with CCUS or LR-MDS
Research has demonstrated that vitamin C plays a role in the activation of TET2, and patients with hematological malignancies are often deficient in vitamin C. In this presentation, Stine Ulrik Mikkelsen, MD, PhD, University of Copenhagen, Copenhagen, Denmark, discusses the Phase II EVI-2 study (NCT03682029), which evaluated the safety and efficacy of vitamin C supplementation in patients with low-risk myeloid malignancies and precursor conditions, including clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndromes (LR-MDS). This press briefing took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
